Skip to main content
. 2021 Jan 19;35(4):938–947. doi: 10.1111/jdv.17002

Figure 3.

Figure 3

IGA mod 2011 0/1 and PASI responses at Week 12 (NRI with extended analysis visit window). ETN, etanercept; HD, high dose; IGA mod 2011, Investigator’s Global Assessment Modified 2011; LD, low dose; NRI, non‐responder imputation; PASI, Psoriasis Area and Severity Index; PBO, placebo; SEC, secukinumab.